Literature DB >> 27933606

Relaxin-like peptides in male reproduction - a human perspective.

Richard Ivell1,2, Alexander I Agoulnik3, Ravinder Anand-Ivell1.   

Abstract

The relaxin family of peptide hormones and their cognate GPCRs are becoming physiologically well-characterized in the cardiovascular system and particularly in female reproductive processes. Much less is known about the physiology and pharmacology of these peptides in male reproduction, particularly as regards humans. H2-relaxin is involved in prostate function and growth, while insulin-like peptide 3 (INSL3) is a major product of the testicular Leydig cells and, in the adult, appears to modulate steroidogenesis and germ cell survival. In the fetus, INSL3 is a key hormone expressed shortly after sex determination and is responsible for the first transabdominal phase of testicular descent. Importantly, INSL3 is becoming a very useful constitutive biomarker reflecting both fetal and post-natal development. Nothing is known about roles for INSL4 in male reproduction and only very little about relaxin-3, which is mostly considered as a brain peptide, or INSL5. The former is expressed at very low levels in the testes, but has no known physiology there, whereas the INSL5 knockout mouse does exhibit a testicular phenotype with mild effects on spermatogenesis, probably due to a disruption of glucose homeostasis. INSL6 is a major product of male germ cells, although it is relatively unexplored with regard to its physiology or pharmacology, except that in mice disruption of the INSL6 gene leads to a disruption of spermatogenesis. Clinically, relaxin analogues may be useful in the control of prostate cancer, and both relaxin and INSL3 have been considered as sperm adjuvants for in vitro fertilization. LINKED ARTICLES: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27933606      PMCID: PMC5406299          DOI: 10.1111/bph.13689

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  130 in total

1.  Evolution and male fertility: lessons from the insulin-like factor 6 gene (Insl6).

Authors:  Richard Ivell; Frank Grutzner
Journal:  Endocrinology       Date:  2009-09       Impact factor: 4.736

2.  Relaxin-like factor: a highly specific and constitutive new marker for Leydig cells in the human testis.

Authors:  R Ivell; M Balvers; R Domagalski; H Ungefroren; N Hunt; W Schulze
Journal:  Mol Hum Reprod       Date:  1997-06       Impact factor: 4.025

Review 3.  Insulin-like factor 3 as a monitor of endocrine disruption.

Authors:  Ravinder Anand-Ivell; Richard Ivell
Journal:  Reproduction       Date:  2014-03-02       Impact factor: 3.906

4.  Expression profiles of relaxin family peptides and their receptors indicate their influence on spermatogenesis in the domestic cat (Felis catus).

Authors:  B C Braun; K Müller; K Jewgenow
Journal:  Domest Anim Endocrinol       Date:  2015-01-28       Impact factor: 2.290

5.  Cryptorchidism in mice with an androgen receptor ablation in gubernaculum testis.

Authors:  Elena M Kaftanovskaya; Zaohua Huang; Agustin M Barbara; Karel De Gendt; Guido Verhoeven; Ivan P Gorlov; Alexander I Agoulnik
Journal:  Mol Endocrinol       Date:  2012-02-09

Review 6.  Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness.

Authors:  Thomas Klonisch; Joanna Bialek; Yvonne Radestock; Cuong Hoang-Vu; Sabine Hombach-Klonisch
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

7.  Normal prostate morphology in relaxin-mutant mice.

Authors:  Avinash Ganesan; Thomas Klonisch; Jonathan T McGuane; Shu Feng; Alexander I Agoulnik; Laura J Parry
Journal:  Reprod Fertil Dev       Date:  2009       Impact factor: 2.311

8.  Expression of the insulin-like peptide 3 (INSL3) hormone-receptor (LGR8) system in the testis.

Authors:  Ravinder J K Anand-Ivell; Vandana Relan; Marga Balvers; Isabelle Coiffec-Dorval; Martin Fritsch; Ross A D Bathgate; Richard Ivell
Journal:  Biol Reprod       Date:  2006-02-08       Impact factor: 4.285

Review 9.  The relaxin family peptide receptors and their ligands: new developments and paradigms in the evolution from jawless fish to mammals.

Authors:  Sergey Yegorov; Jan Bogerd; Sara V Good
Journal:  Gen Comp Endocrinol       Date:  2014-07-29       Impact factor: 2.822

10.  Establishing the "Biological Relevance" of Dipentyl Phthalate Reductions in Fetal Rat Testosterone Production and Plasma and Testis Testosterone Levels.

Authors:  Leon Earl Gray; Johnathan Furr; Katoria R Tatum-Gibbs; Christy Lambright; Hunter Sampson; Bethany R Hannas; Vickie S Wilson; Andrew Hotchkiss; Paul M D Foster
Journal:  Toxicol Sci       Date:  2015-10-09       Impact factor: 4.849

View more
  12 in total

1.  Recent progress in the understanding of relaxin family peptides and their receptors.

Authors:  R J Summers
Journal:  Br J Pharmacol       Date:  2017-05       Impact factor: 8.739

2.  Genetic analysis of the human insulin-like 3 gene in pediatric patients with testicular torsion.

Authors:  Anna Paola Capra; Elisa Ferro; Maria Angela La Rosa; Silvana Briuglia; Tiziana Russo; Salvatore Arena; Carmelo Salpietro Damiano; Carmelo Romeo; Pietro Impellizzeri
Journal:  Pediatr Surg Int       Date:  2018-05-21       Impact factor: 1.827

Review 3.  Relaxin-like peptides in male reproduction - a human perspective.

Authors:  Richard Ivell; Alexander I Agoulnik; Ravinder Anand-Ivell
Journal:  Br J Pharmacol       Date:  2017-02-27       Impact factor: 8.739

4.  Development of a selective agonist for relaxin family peptide receptor 3.

Authors:  Dian Wei; Meng-Jun Hu; Xiao-Xia Shao; Jia-Hui Wang; Wei-Han Nie; Ya-Li Liu; Zeng-Guang Xu; Zhan-Yun Guo
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

5.  Protective Role of Testicular Hormone INSL3 From Atrophy and Weakness in Skeletal Muscle.

Authors:  Alberto Ferlin; Luca De Toni; Alexander I Agoulnik; Giorgia Lunardon; Andrea Armani; Sergia Bortolanza; Bert Blaauw; Marco Sandri; Carlo Foresta
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-28       Impact factor: 5.555

6.  Relaxin Family Member Insulin-Like Peptide 6 Ameliorates Cardiac Fibrosis and Prevents Cardiac Remodeling in Murine Heart Failure Models.

Authors:  Sonomi Maruyama; Chia-Ling Wu; Sumiko Yoshida; Dongying Zhang; Pei-Hsuan Li; Fangzhou Wu; Jennifer Parker Duffen; Rouan Yao; Blake Jardin; Ibrahim M Adham; Ronald Law; Joel Berger; Richard Di Marchi; Kenneth Walsh
Journal:  J Am Heart Assoc       Date:  2018-06-10       Impact factor: 5.501

7.  Insulin-Like Peptide 3 (INSL3) Serum Concentration During Human Male Fetal Life.

Authors:  Steven M Harrison; Nicol Corbin Bush; Yi Wang; Zachary R Mucher; Armando J Lorenzo; Gwen M Grimsby; Bruce J Schlomer; Erika E Büllesbach; Linda A Baker
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-04       Impact factor: 5.555

8.  Insulin-like 3 affects zebrafish spermatogenic cells directly and via Sertoli cells.

Authors:  Diego Crespo; Luiz H C Assis; Yu Ting Zhang; Diego Safian; Tomasz Furmanek; Kai Ove Skaftnesmo; Birgitta Norberg; Wei Ge; Yung-Ching Choi; Marjo J den Broeder; Juliette Legler; Jan Bogerd; Rüdiger W Schulz
Journal:  Commun Biol       Date:  2021-02-15

9.  Prepubertal nutrition alters Leydig cell functional capacity and timing of puberty.

Authors:  Ravinder Anand-Ivell; Colin J Byrne; Jonas Arnecke; Sean Fair; Pat Lonergan; David A Kenny; Richard Ivell
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

10.  Mass Spectrometry Supports That the Structure of Circulating Human Insulin-Like Factor 3 Is a Heterodimer.

Authors:  Jakob Albrethsen; Anders Juul; Anna-Maria Andersson
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-28       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.